Dr. Krishna Menon, Chief Scientific Officer for Cellceutix, commented, "There has been a big movement in oncology research to establish new biomarkers as they are an earlier measure of activity in the body's cells.  p21 has been proven to play a critical role in cell cycle arrest leading to cell death.  No one has been able to validate it as a biomarker, to the best of our knowledge, so this will be a major event not only for Cellceutix, but for the cancer clinical trials."  Dr. Menon continued, "Increased levels of p21 are not only a predictor of cell death, but a benchmark in judging effectiveness of Kevetrin™.  Our pre-clinical research on p21 has met its endpoints and we are optimistic that the upcoming human trials will yield similar results."